SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending intensely as a recent partnership with Novo Nordisk has resolved a major legal overhang, igniting a fervent community belief in an impending short squeeze due to high short interest and the perceived destruction of the bear thesis in the GLP-1 market.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is surging after reporting strong earnings, driven by explosive AI-driven cloud infrastructure growth and a massive increase in remaining performance obligations, which has ignited a fierce debate among investors eager to capitalize on the stock's AI transformation while others anticipate profit-taking and a potential fade.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSS Inc. is trending after reporting a strong Q4 and full-year earnings beat, highlighting significant growth in its AI rack integration business and securing a two-year extension with its largest customer, Dell. The community is actively discussing TSSI's crucial role in the booming AI infrastructure buildout, driven by Dell's escalating AI server backlog, with many anticipating substantial price appreciation and a potential short squeeze.

The Campbell's Co. engages in the business of manufacturing and marketing food and beverage products. It operates under the Meals and Beverages, and Snacks segments. The Meals and Beverages segment includes soup, meals, and beverage products in retail and foodservice. The Snacks segment offers cookies, crackers, bakery, and frozen products. The company was founded by Joseph Campbell and Abraham Anderson in 1869 and is headquartered in Camden, NJ.

Campbells Co (The)

Campbell Soup Co.

Campbell Soup is trending as its Q2 earnings report revealed a significant drop in EPS and a lowered full-year outlook, fueling community debate about the compounding impact of GLP-1 drugs and tariffs on processed food demand, with investors divided between calling it a value trap or a deep-value opportunity.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending on widespread anticipation of a significant hyperscaler tenant announcement for its Texas Critical Data Centers campus, strategically located for AI workloads requiring substantial and reliable behind-the-meter power. The community actively discusses the delayed tenant reveal, recent land acquisition, and a 450 MW generation plan, while also navigating a selling stockholder offering amidst strong short interest.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as its new SiC power solutions, critical for advancing AI data center efficiency and high-power applications, are generating significant community buzz. Investors are closely watching for potential partnership announcements, particularly in connection with major AI players, despite discussions around its current revenue figures and high short interest.

Domo, Inc. designs, develops, and markets executive management software solutions. It offers customized software tools for business operations, customer relationship management, human resources, and financial reporting. The company was founded by Joshua G. James in September 2010 and is headquartered in American Fork, UT.

Domo Inc. - Ordinary Shares - Class B

Domo Inc.

Domo Inc. is trending following better-than-expected earnings, marked by improved cash generation and profitability, alongside news of the company actively exploring strategic alternatives. This has sparked a lively debate among traders, with many anticipating further upside from potential M&A or renewed interest in AI data analytics, while others remain wary of the company's historical volatility and debt.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as the market fiercely debates whether the International Energy Agency's historic 400 million barrel oil reserve release will effectively counter escalating geopolitical tensions and potential blockades in the Strait of Hormuz. Conflicting reports regarding the strait's navigability are fueling extreme price volatility and a divided community outlook.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is actively discussed after its Q4 earnings highlighted strong revenue growth and increased 2026 guidance, alongside expanding autonomous delivery with White Castle on Uber Eats and a strategic healthcare robotics acquisition. This confluence of developments is driving community debate on its significant valuation against its long-term potential in the burgeoning physical AI sector.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending after its earnings report delivered flat comparable sales guidance for the coming year, intensifying community criticism regarding management's perceived elitist strategy and declining customer value. This has fueled widespread investor frustration over the stock's underperformance in a competitive fast-casual sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OS Therapies (NYSE-A: $OSTX) reported statistically significant positive 2-year overall survival results from an interim analysis of its Phase 2b trial of its off-the-shelf immunotherapy candidate OST-HER2 for preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. 
 
OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1. 
 
The company also announced its NYSE American listing has been added to the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes. FTSE Russell determines membership for its Russell indexes based on objective, market-capitalization rankings, and style attributes. Investment managers and institutional investors widely use Russell indexes for index funds and as benchmarks for active investment strategies. 
 
Highlights from today’s news release include: 
 
- 66.6% of patients treated with OST-HER2 (18/27) reached 2-year overall survival versus 40% in historical controls (p = 0.0046). 
 
- The FDA issued a Biologics License Application (BLA) number for OST-HER2 ahead of the anticipated filing following the pending August 27, 2025, End of Phase 2 Meeting. 
 
- The company is working with the FDA to align metrics for Regenerative Medicine Advanced Therapy (RMAT) designation, Breakthrough Therapy Designation (BTD), and BLA through the Accelerated Approval pathway. 
 
Paul Romness, MPH, Chairman &amp; CEO of OS Therapies, remarked, “We are seeking to bring this novel immunotherapy to market to improve the survival rates in pulmonary metastatic osteosarcoma, and today’s updated interim overall survival data continues to show a statistically significant benefit for OST-HER2-treated patients compared with control. We believe that continued statistically significant outperformance in overall survival of OST-HER2 treated patients compared with historical control, together with the statistically significant positive 12-month Event Free Survival data presented at MIB Factor in June 2025, will provide the necessary scientific and medical basis to support a BLA under the FDA’s Accelerated Approval Program.” 
 
Read the full release at: https://ir.ostherapies.com/news-events/press-releases/detail/72/os-therapies-announces-statistically-significant-positive 
 
Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. 
 
Learn more about OS Therapies’ work at https://www.ostherapies.com and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com. 
 
Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/os-therapies-1 $THTX $CGTX

Raimundas Veitas

Dexter Rivington

David Shapiro

Brogley Panzarella

Slade Magat

Xylia Fluetsch

Illescas Gibes

Refugio Bergstrom

top moon

Nils Vrooman

Cal Dwan

Pablo Rodriguez

Ariana Storck

Joseph Forbes

Jack Tharpe

Heidi Campbell

Guillermo Oneill

Amie Fazio

Shirley Hall

Virgil Bowen

Clarice Hasselman

Greg Harrison

Stephan Breeden

Renee Blankenship

Nina Studdard

James Williams

StockTwits Web

OS Therapies Inc

Theratechnologies Inc.

Cognition Therapeutics Inc

) reported statistically significant positive 2-year overall survival results from an interim analysis of its Phase 2b trial of its off-the-shelf immunotherapy candidate OST-HER2 for preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. 
 
OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at 

. 
 
The company also announced its NYSE American listing has been added to the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes. FTSE Russell determines membership for its Russell indexes based on objective, market-capitalization rankings, and style attributes. Investment managers and institutional investors widely use Russell indexes for index funds and as benchmarks for active investment strategies. 
 
Highlights from today’s news release include: 
 
- 66.6% of patients treated with OST-HER2 (18/27) reached 2-year overall survival versus 40% in historical controls (p = 0.0046). 
 
- The FDA issued a Biologics License Application (BLA) number for OST-HER2 ahead of the anticipated filing following the pending August 27, 2025, End of Phase 2 Meeting. 
 
- The company is working with the FDA to align metrics for Regenerative Medicine Advanced Therapy (RMAT) designation, Breakthrough Therapy Designation (BTD), and BLA through the Accelerated Approval pathway. 
 
Paul Romness, MPH, Chairman & CEO of OS Therapies, remarked, “We are seeking to bring this novel immunotherapy to market to improve the survival rates in pulmonary metastatic osteosarcoma, and today’s updated interim overall survival data continues to show a statistically significant benefit for OST-HER2-treated patients compared with control. We believe that continued statistically significant outperformance in overall survival of OST-HER2 treated patients compared with historical control, together with the statistically significant positive 12-month Event Free Survival data presented at MIB Factor in June 2025, will provide the necessary scientific and medical basis to support a BLA under the FDA’s Accelerated Approval Program.” 
 
Read the full release at: 

 
 
Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. 
 
Learn more about OS Therapies’ work at 

 and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com. 
 
Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of 

Applied Energetics, Inc.

SuperCom Ltd

Applied Dna Sciences Inc

Unicycive Therapeutics Inc

Heidmar Maritime Holdings Corp. Common Stock

eXoZymes Inc.

Kolibri Global Energy Inc

Explore OS Therapies&#39; full company profile, including updates on OST-HER2 and its regulatory progress, at https://b2idigital.com/os-therapies-1. Stay informed on their mission to deliver breakthrough immunotherapies for hard-to-treat cancers.

OS Therapies is dedicated to developing innovative cancer treatments, including immunotherapies that harness the immune system to fight tumors and advanced drug technologies designed to deliver chemotherapy more precisely to cancer cells while reducing side effects.

B2idigital

OS Therapies, Inc. (NYSE-A: OSTX) Profile on B2i Digital

Explore OS Therapies' full company profile, including updates on OST-HER2 and its regulatory progress, at 

. Stay informed on their mission to deliver breakthrough immunotherapies for hard-to-treat cancers.